Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in this application:

Listing of Claims:

- (Previously presented) A method for suppressing proliferation of abnormal prion proteins, comprising systemically, orally, intracerebrally or intraspinally administering to a patient in need thereof an essential amino acid having a branched side chain.
- (Previously presented) The method according to claim 1, wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof.
- 3. (Previously presented) The method according to claim 2, wherein said amino acid having a branched side chain is leucine.
- 4. (Previously presented) A method for providing an essential amino acid having a branched side chain to a patient in need thereof, comprising systemically, orally, intracerebrally or intraspinally administering said essential amino acid having a branched side chain so as to suppress proliferation of abnormal prion proteins.
- (Previously presented) The method according to claim 4, wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof.
- (Previously presented) The method according to claim 4, wherein said essential amino acid having a branched side chain is leucine.

- 7. (Original) A suppressive agent containing an essential amino acid having a branched side chain as an active ingredient for suppressing proliferation of abnormal prion proteins.
- 8. (Previously presented) The suppressive agent according to claim 7. wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof.
- 9. (Previously presented) The suppressive agent according to claim 8. wherein the essential amino acid having a branched side chain is leucine.

10-12. (Cancelled)

- 13. (Currently amended) A method for treating preventing prion diseases by suppressing proliferation of abnormal prion proteins which comprises systemically, or ally, intracerebrally or intraspinally administering to a patient in need thereof an essential amino acid having a branched side chain as an active ingredient.
- 14. (Previously presented) The method according to claim 13, wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof,
- 15. (Original) The method according to claim 13, wherein the essential amino acid having a branched side chain is leucine.
- 16. (Previously presented) The method according to claim 13, wherein said prion disease is scrapie.

- 17. (Previously presented) The method according to claim 13, wherein said prion disease is bovine spongiform encephalopathy (BSE).
- (Previously presented) The method according to claim 13, wherein said prion disease is Creutzfeldt-Jakob disease (CJD).
- (Previously presented) The method according to claim 13, wherein said prion disease is Gerstmann-Straussler-Scheinker syndrome.